ACADIA Pharmaceuticals (ACAD) is back in focus after two recent product related updates, including broader U.S. availability of DAYBUE STIX for Rett syndrome and upcoming data presentations across its neurology portfolio at the 2026 AAN meeting.

Recent announcements on broader U.S. availability of DAYBUE STIX and the upcoming neurology data presentations appear to sit behind a 9.10% 1 month share price return. This comes even as the 90 day share price return shows a 14.70% decline, which contrasts with a 50.51% 1 year total shareholder return. This pattern suggests long term momentum alongside near term volatility.

If you are curious about other opportunities around neurology and rare disease treatments, it could be a good moment to scout 35 healthcare AI stocks

With ACADIA trading at US$22.17, sitting below the US$31.80 analyst target and flagged with an intrinsic discount, the key question for you is simple: is this an inefficiency to exploit or is the market already baking in future growth?

Most Popular Narrative: 22.9% Undervalued

ACADIA's latest close of $22.17 sits below the $28.75 fair value indicated in the most followed narrative, setting up a clear valuation gap for investors to assess.

From an investor standpoint, ACADIA’s challenge is balancing clinical ambition with financial discipline. Research and development costs remain elevated, and revenue concentration increases sensitivity to any disruption, whether regulatory, competitive, or reimbursement-related.

At the same time, success in even a limited number of indications can generate meaningful cash flow if adoption remains steady. This creates a setup where the downside is well understood, but the upside depends on disciplined execution rather than speculative breakthroughs.

Want to see what sits behind that gap between price and fair value? The narrative emphasizes sustained earnings expansion, firm margins, and a future profit profile that treats ACADIA more like a scaled specialty pharma player than a single asset biotech.

Result: Fair Value of $28.75 (UNDERVALUED)

However, this hinges on continued execution, with risks around ACADIA’s concentrated U.S. revenue base and the uncertainty attached to its largely early to mid stage neurology pipeline.

Next Steps

Given the current mix of optimism and caution, it may be useful to look at the numbers yourself and decide how comfortable you feel with the story. To see what the market is currently rewarding and why sentiment may be optimistic around ACADIA, review the 4 key rewards

Looking for more investment ideas?

If ACADIA has caught your attention, do not stop here. Use the Simply Wall Street Screener to uncover more ideas that could fit your approach.

• Target resilient compounders by scanning 70 resilient stocks with low risk scores that aim to balance growth potential with a focus on risk controls and financial resilience.
• Spot potential mispricings early by reviewing screener containing 23 high quality undiscovered gems that pair solid fundamentals with relatively low investor attention.
• Build a sturdier core for your portfolio by focusing on companies in the solid balance sheet and fundamentals stocks screener (42 results) that prioritize financial strength and flexibility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.